Search results for "patho"

showing 10 items of 10772 documents

Protein misfolding, amyotrophic lateral sclerosis and guanabenz: Protocol for a phase II RCT with futility design (ProMISe trial)

2017

IntroductionRecent studies suggest that endoplasmic reticulum stress may play a critical role in the pathogenesis of amyotrophic lateral sclerosis (ALS) through an altered regulation of the proteostasis, the cellular pathway-balancing protein synthesis and degradation. A key mechanism is thought to be the dephosphorylation of eIF2α, a factor involved in the initiation of protein translation. Guanabenz is an alpha-2-adrenergic receptor agonist safely used in past to treat mild hypertension and is now an orphan drug. A pharmacological action recently discovered is its ability to modulate the synthesis of proteins by the activation of translational factors preventing misfolded protein accumula…

0301 basic medicineOncologyPathologyamyotrophic lateral sclerosisamyotrophic lateral sclerosis; motor neurone disease; neuromuscular disease; randomized clinical trial guanabenz; unfolded protein response; adrenergic alpha-2 receptor agonist s; age of onset; amyotrophic lateral sclerosis; disease progression; double-blind method; endoplasmic reticulum stress; guanabenz; humans; italy; medical futility; neuroprotective agents; proteostasis deficienciesamyotrophic lateral sclerosis; motor neurone disease; neuromuscular disease; randomized clinical trial guanabenz; unfolded protein response; Medicine (all)randomized clinical trial guanabenzHelsinki declaration0302 clinical medicineProtocolAdrenergic alpha-2 Receptor Agonists1506Amyotrophic lateral sclerosisAge of OnsetGuanabenzMedicine (all)amyotrophic lateral sclerosis; motor neurone disease; neuromuscular disease; randomized clinical trial guanabenz; unfolded protein responseNeurodegenerationamyotrophic lateral sclerosis; motor neurone disease; neuromuscular disease; randomized clinical trial guanabenz; unfolded protein response;amyotrophic lateral sclerosis; guanabenz; motor neurone disease; neuromuscular disease; randomized clinical trial; unfolded protein response; Adrenergic alpha-2 Receptor Agonists; Age of Onset; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Endoplasmic Reticulum Stress; Guanabenz; Humans; Italy; Medical Futility; Neuroprotective Agents; Proteostasis DeficienciesGeneral Medicineunfolded protein responseEndoplasmic Reticulum StressRiluzoleNeuroprotective AgentsNeurologyTolerabilityItalyDisease Progression1713GuanabenzMedical Futilitymedicine.drugmedicine.medical_specialtyamyotrophic lateral sclerosis; motor neurone disease; neuromuscular disease; randomized clinical trial guanabenz; unfolded protein response; Adrenergic alpha-2 Receptor Agonists; Age of Onset; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Endoplasmic Reticulum Stress; Guanabenz; Humans; Italy; Medical Futility; Neuroprotective Agents; Proteostasis Deficiencies; Medicine (all)Neuroprotection03 medical and health sciencesmotor neurone diseaseDouble-Blind MethodInternal medicinemedicineHumansProteostasis Deficienciesbusiness.industryAmbientaleneuromuscular diseaserandomized clinical trialmedicine.diseaseClinical trial030104 developmental biologybusiness030217 neurology & neurosurgery
researchProduct

BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients

2020

In the era of personalized medicine, BRAF mutational assessment is mandatory in advanced-stage melanoma and non-small cell lung cancer (NSCLC) patients. The identification of actionable mutations is crucial for the adequate management of these patients. To date various drugs have been implemented in clinical practice. Similarly, various methods may be adopted for the identification of BRAF mutations. Here, we briefly review the current literature on BRAF in melanoma and NSCLC, focusing attention in particular on the different methods and drugs adopted in these patients. In addition, an overview of the real-world practice in different Italian laboratories with high expertise in molecular pre…

0301 basic medicineOncologyProto-Oncogene Proteins B-rafmedicine.medical_specialtyPredictive molecular pathologyLung NeoplasmsGene mutationBRAF03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungMedicineHumansNon-Small-Cell LungVemurafenibLung cancerneoplasmsMelanomaTrametinibCobimetinibbusiness.industryBRAF; Lung cancer; Melanoma; Precision medicine; Predictive molecular pathology; Biomarkers; Humans; Mutation; Proto-Oncogene Proteins B-raf; Carcinoma Non-Small-Cell Lung; Lung Neoplasms; MelanomaCarcinomaPrecision medicineDabrafenibHematologyBiomarkerPrecision medicinemedicine.diseaseBRAF; Lung cancer; Melanoma; Precision medicine; Predictive molecular pathologyLung Neoplasm030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisMutationPersonalized medicineLung cancerbusinessBiomarkersmedicine.drugHuman
researchProduct

Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients

2017

Background: Results from the BEVA2007 trial, suggest that the metronomic chemotherapy regimen with dose-fractioned cisplatin and oral etoposide (mPE) +/− bevacizumab, a monoclonal antibody to the vascular endothelial growth factor (VEGF), shows anti-angiogenic and immunological effects and is a safe and active treatment for metastatic non-small cell lung cancer (mNSCLC) patients. We carried out a retrospective analysis aimed to evaluate the antitumor effects of this treatment in a subset of patients with squamous histology. Methods: Retrospective analysis was carried out in a subset of 31 patients with squamous histology enrolled in the study between September 2007 and September 2015. All o…

0301 basic medicineOncologyPulmonary and Respiratory Medicinemedicine.medical_specialtyPathologyBevacizumabmedicine.medical_treatmentSquamous-NSCLC (sqNSCLC)03 medical and health sciences0302 clinical medicineInternal medicinemedicineProgression-free survivalRadical surgeryEtoposideEtoposideChemotherapybusiness.industryMetronomic chemotherapyCancermedicine.diseaseMetronomic ChemotherapyBevacizumabRegimen030104 developmental biology030220 oncology & carcinogenesisOriginal ArticleCisplatinbusinessBevacizumab; Cisplatin; Etoposide; Metronomic chemotherapy; Squamous-NSCLC (sqNSCLC); Pulmonary and Respiratory Medicinemedicine.drug
researchProduct

Exosomes in lung cancer liquid biopsies: Two sides of the same coin?

2017

LETTER TO EDITOR

0301 basic medicineOncologyPulmonary and Respiratory Medicinemedicine.medical_specialtyPathologyCancer ResearchLung NeoplasmsMEDLINEExosomes03 medical and health sciences0302 clinical medicineInternal medicinemedicineBiomarkers TumorHumansLiquid biopsyLung cancerbusiness.industryLiquid Biopsymedicine.diseaseMicrovesicles030104 developmental biologyOncology030220 oncology & carcinogenesisHuman medicinebusinessOncology; Pulmonary and Respiratory Medicine; Cancer Research
researchProduct

Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer

2019

Background: VEGF-A, VEGF-B, VEGFR-1 and VEGFR-2 are important proteins involved in the induction and development of a new blood vessel network through which the tumor is properly nourished and oxygenated. Objective: The aim of the study was to evaluate changes in VEGF-A, VEGF-B, VEGFR-1 and VEGFR-2 expression in endometrial cancer depending on its grade and to determine the VEGFR-1 to VEGFR-2 concentration ratio. Methods: The study group consisted of 45 patients diagnosed with endometrial cancer (G1, 17; G2, 15; G3, 13). The control group included 15 patients. VEGF-A, VEGF-B, VEGF-R1, VEGFR-2 expression was assessed using the immunohistochemical method. Statistical analysis was carried out…

0301 basic medicineOncologyTumor angiogenesisVascular Endothelial Growth Factor Amedicine.medical_specialtyVascular Endothelial Growth Factor BVEGF-A/BAngiogenesisPharmaceutical ScienceArticle03 medical and health sciencesangiogenesis0302 clinical medicineInternal medicineMedicineHumansAdenomyosisRNA MessengerVascular Endothelial Growth Factor Receptor-1integumentary systemNeovascularization Pathologicbusiness.industryEndometrial cancerCancerVEGFR-1/2tumor angiogenesismedicine.diseasePrognosisImmunohistochemistryVascular Endothelial Growth Factor Receptor-2Endometrial Neoplasms030104 developmental biologymedicine.anatomical_structureadenomyosis030220 oncology & carcinogenesisCase-Control Studiesembryonic structuresendometrial cancercardiovascular systemImmunohistochemistryFemaleAnalysis of varianceNeoplasm GradingbusinessBiotechnologyBlood vesselCurrent Pharmaceutical Biotechnology
researchProduct

International consensus guidelines for scoring the histopathological growth patterns of liver metastasis

2017

BACKGROUND: Liver metastases present with distinct histopathological growth patterns (HGPs), including the desmoplastic, pushing and replacement HGPs and two rarer HGPs. The HGPs are defined owing to the distinct interface between the cancer cells and the adjacent normal liver parenchyma that is present in each pattern and can be scored from standard haematoxylin-and-eosin-stained (H&E) tissue sections. The current study provides consensus guidelines for scoring these HGPs.METHODS: Guidelines for defining the HGPs were established by a large international team. To assess the validity of these guidelines, 12 independent observers scored a set of 159 liver metastases and interobserver var…

0301 basic medicineOncologycongenital hereditary and neonatal diseases and abnormalitiesCancer Researchmedicine.medical_specialtyPathologyIntraclass correlationmedicine.medical_treatmentcolorectal cancerGuidelineMetastasisangiogenesis03 medical and health sciencesbreast cancer0302 clinical medicineSDG 3 - Good Health and Well-beingInternal medicineJournal ArticlemedicineHumansNeoplasm Metastasisprognostic factorintegumentary systembusiness.industryLiver Neoplasmsnutritional and metabolic diseasesvessel co-optionGold standard (test)medicine.diseaseliver metastasis030104 developmental biologyTissue sectionsPractice GuidelineOncology030220 oncology & carcinogenesisCancer cellCohortBiomarker (medicine)Hepatectomytumour microenvironmentbusinessBritish Journal of Cancer
researchProduct

Therapeutic Plasmapheresis with Albumin Replacement in Alzheimer’s Disease and Chronic Progressive Multiple Sclerosis: A Review

2020

Background: Reducing the burden of beta-amyloid accumulation and toxic autoimmunity-related proteins, one of the recognized pathophysiological markers of chronic and common neurological disorders such as Alzheimer’s disease (AD) and multiple sclerosis (MS), may be a valid alternative therapy to reduce their accumulation in the brain and thus reduce the progression of these disorders. The objective of this review was to evaluate the efficacy of plasmapheresis (PP) in AD and chronic progressive MS patients (in terms of improving clinical symptoms) and to analyze its safety and protocols. Methods: Articles related to this topic and published without time limitations in the Medline, and C…

0301 basic medicineOncologymedicine.medical_specialtyAmyloid betamedicine.medical_treatmentPharmaceutical Sciencelcsh:Medicinelcsh:RS1-441DiseaseReviewlcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoverymedicineVerbal fluency testDementiamagnetic resonance imagingauto-immunityalbuminbiologybusiness.industryMultiple sclerosislcsh:Rmedicine.diseasePathophysiologyamyloid beta030104 developmental biologyplasmapheresisToxicitybiology.proteinMolecular MedicinePlasmapheresisbusiness030217 neurology & neurosurgerydementiaPharmaceuticals
researchProduct

Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer

2016

Colorectal cancer is the third most common cancer worldwide. The prognosis of colorectal cancer patients still remains dismal and half of them will develop metastatic disease. Angiogenesis plays an essential role in colorectal tumorigenesis, and the VEGF pathway is one of the targets that has been validated up to now. The use of antiangiogenics along with chemotherapy has become an accepted standard for colorectal cancer.This review discusses the efficacy and safety profile of ramucirumab, a fully human immunoglobulin G1 monoclonal antibody against the vascular endothelial growth factor receptor-2 (VEGFR-2), for the treatment of second-line metastatic colorectal cancer upon progression to f…

0301 basic medicineOncologymedicine.medical_specialtyBevacizumabAngiogenesisColorectal cancermedicine.medical_treatmentDrug Evaluation PreclinicalAngiogenesis InhibitorsDiseaseAntibodies Monoclonal HumanizedToxicologyRamucirumab03 medical and health scienceschemistry.chemical_compoundClinical Trials Phase II as Topic0302 clinical medicineInternal medicinemedicineAnimalsHumansRandomized Controlled Trials as TopicPharmacologyChemotherapyClinical Trials Phase I as TopicNeovascularization Pathologicbusiness.industryAntibodies MonoclonalCancerGeneral Medicinemedicine.diseaseVascular endothelial growth factorDisease Models Animal030104 developmental biologyClinical Trials Phase III as Topicchemistry030220 oncology & carcinogenesisColorectal Neoplasmsbusinessmedicine.drugExpert Opinion on Drug Metabolism & Toxicology
researchProduct

Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma

2021

BACKGROUND: Targeted genetic profiling of tissue samples is paramount to detect druggable genetic aberrations in patients with non-squamous non-small cell lung cancer (NSCLC). Accurate upfront estimation of tumor cell content (TCC) is a crucial pre-analytical step for reliable testing and to avoid false-negative results. As of now, TCC is usually estimated on hematoxylin-eosin (H&E) stained tissue sections by a pathologist, a methodology that may be prone to substantial intra- and interobserver variability. Here we the investigate suitability of digital pathology for TCC estimation in a clinical setting by evaluating the concordance between semi-automatic and conventional TCC quantification…

0301 basic medicineOncologymedicine.medical_specialtyConcordanceTumor cellsurologic and male genital diseases03 medical and health sciences0302 clinical medicineInternal medicineMedicineLung cancerneoplasmsLungbusiness.industryMolecular pathologyDigital pathologymedicine.diseasefemale genital diseases and pregnancy complicationsddc:030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisAdenocarcinomaOriginal ArticleSemi automaticbusiness
researchProduct

Asynchronous and pathological windows of implantation: two causes of recurrent implantation failure

2018

STUDY QUESTION: Is endometrial recurrent implantation failure (RIF) only a matter of an asynchronous (displaced) window of implantation (WOI), or could it also be a pathological (disrupted) WOI? SUMMARY ANSWER: Our predictive results demonstrate that both displaced and disrupted WOIs exist and can present independently or together in the same RIF patient. WHAT IS KNOWN ALREADY: Since 2002, many gene expression signatures associated with endometrial receptivity and RIF have been described. Endometrial transcriptomics prediction has been applied to the human WOI in two previous studies. One study describes endometrial RIF to be the result of a temporal displacement of the WOI. The other indic…

0301 basic medicineOncologymedicine.medical_specialtyConcordanceprecision medicineBiologyEndometrial tissue03 medical and health sciencesEndometrium0302 clinical medicineImplantation failuretranscriptomic predictorsInternal medicinemedicinepolycyclic compoundsHumansendometrial asynchronyEmbryo Implantationendometrial pathologyendometriumPathologicalRetrospective Studiesrecurrent implantation failure030219 obstetrics & reproductive medicineGene Expression ProfilingRehabilitationConfoundingObstetrics and GynecologyRetrospective cohort studyEmbryo TransferPenetranceGene expression profilinggene expression signatures030104 developmental biologyReproductive Medicinemachine learning predictorswindow of implantation displacementFemaleTranscriptomeInfertility Femaletranscriptomic taxonomy
researchProduct